Karger Publishers
Browse

Supplementary Material for: Successful Response to First-Line Carboplatin, Pemetrexed, and Bevacizumab for Peritoneal Mesothelioma –Two Case Reports–

Download (1.33 MB)
dataset
posted on 2025-01-30, 11:52 authored by Koizumi T., Kanda S., Sekiguchi N., Noguchi T., Eda S., Kitahara H.
Introduction; Peritoneal mesothelioma is an extremely rare malignancy of the peritoneum. It has a poor prognosis, and the optimal systemic chemotherapy remains controversial. Here, we report two cases of peritoneal mesothelioma with long-term survival and complete response to carboplatin, pemetrexed, and bevacizumab chemotherapy. Case presentation; Both patients were treated with six cycles of carboplatin (AUC 5), pemetrexed (750 mg/m2), and bevacizumab (15 mg/kg) followed by pemetrexed and bevacizumab as maintenance therapy. Partial response continued for over 6 years in case 1 and complete response was obtained in case 2. The patient in case 1 died after 7 years due to accidental pneumonia, and the patient in case 2 remained disease-free for over 2 years after initiation of chemotherapy. Conclusion; Little information is available regarding angiogenesis in malignant peritoneal mesothelioma and carboplatin/pemetrexed/bevacizumab ae off-labeled chemotherapy by Japanese healthcare system as yet. However, our experience suggested that combined chemotherapy with bevacizumab is a feasible option fir systemic chemotherapy in cases of peritoneal mesothelioma.

History

Usage metrics

    Case Reports in Oncology

    Categories

    Keywords

    Licence

    Exports

    RefWorks
    BibTeX
    Ref. manager
    Endnote
    DataCite
    NLM
    DC